HK1207114A1 - Compositions and methods of obtaining and using endoderm and hepatocyte cells - Google Patents
Compositions and methods of obtaining and using endoderm and hepatocyte cellsInfo
- Publication number
- HK1207114A1 HK1207114A1 HK15107688.5A HK15107688A HK1207114A1 HK 1207114 A1 HK1207114 A1 HK 1207114A1 HK 15107688 A HK15107688 A HK 15107688A HK 1207114 A1 HK1207114 A1 HK 1207114A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- endoderm
- compositions
- obtaining
- methods
- hepatocyte cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0613—Cells from endocrine organs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
- C12N5/0678—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650762P | 2012-05-23 | 2012-05-23 | |
PCT/EP2013/060372 WO2013174794A1 (en) | 2012-05-23 | 2013-05-21 | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207114A1 true HK1207114A1 (en) | 2016-01-22 |
Family
ID=48483066
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107688.5A HK1207114A1 (en) | 2012-05-23 | 2015-08-10 | Compositions and methods of obtaining and using endoderm and hepatocyte cells |
HK16102908.9A HK1215043A1 (zh) | 2012-05-23 | 2016-03-14 | 獲得和使用內胚層和肝細胞的組合物和方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16102908.9A HK1215043A1 (zh) | 2012-05-23 | 2016-03-14 | 獲得和使用內胚層和肝細胞的組合物和方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20170002313A1 (xx) |
EP (1) | EP2852661A1 (xx) |
JP (2) | JP6301316B2 (xx) |
KR (4) | KR20160027218A (xx) |
CN (2) | CN104350144B (xx) |
BR (1) | BR112014028881A2 (xx) |
CA (1) | CA2868392A1 (xx) |
HK (2) | HK1207114A1 (xx) |
MX (1) | MX2014013725A (xx) |
RU (1) | RU2014149145A (xx) |
WO (1) | WO2013174794A1 (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
CN104694456B (zh) * | 2013-12-06 | 2018-05-29 | 中国科学院上海药物研究所 | 体外培养肝样细胞的方法及采用该方法培养的优化后肝样细胞 |
US9404086B2 (en) * | 2014-03-26 | 2016-08-02 | Ge Healthcare Uk Limited | Method for cell differentiation |
EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
EP3207123A1 (en) * | 2014-10-17 | 2017-08-23 | Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
JP5777127B1 (ja) * | 2014-12-09 | 2015-09-09 | 公立大学法人横浜市立大学 | 原始腸内胚葉細胞及びその作製方法 |
JPWO2016104541A1 (ja) * | 2014-12-24 | 2017-10-05 | 国立大学法人京都大学 | 内胚葉系細胞の製造方法、肝臓細胞の製造方法、膵臓細胞の製造方法、内胚葉系細胞の誘導促進剤、肝臓細胞の誘導促進キット、膵臓細胞の誘導促進キット、およびマイクロ流体デバイス |
CN104655879A (zh) * | 2015-03-05 | 2015-05-27 | 北京大学第三医院 | 一种应用原子力显微镜检测宫颈脱落细胞刚度的方法 |
WO2017073740A1 (ja) * | 2015-10-29 | 2017-05-04 | 学校法人埼玉医科大学 | 膵内分泌細胞の製造方法、及び分化転換剤 |
CA3016641A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
US11634686B2 (en) | 2016-11-01 | 2023-04-25 | Jian Feng | Method of producing naive pluripotent stem cells |
WO2018106628A1 (en) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
CN110392735A (zh) * | 2017-01-17 | 2019-10-29 | 新加坡科技研究局 | 胰腺祖细胞的维持和扩增 |
WO2018152120A1 (en) * | 2017-02-14 | 2018-08-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
CN107043742A (zh) * | 2017-06-20 | 2017-08-15 | 青岛金典生化器材有限公司 | 一种培养肝细胞的无血清培养基及其制备方法 |
US20200308538A1 (en) * | 2017-09-12 | 2020-10-01 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating liver disease and dysfunction |
CN107937332A (zh) * | 2017-12-04 | 2018-04-20 | 江苏省中医药研究院 | 一种诱导小鼠胰腺导管细胞向胰岛β细胞分化的方法 |
CA3101227A1 (en) * | 2018-05-30 | 2019-12-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof |
KR20210077698A (ko) * | 2018-10-15 | 2021-06-25 | 사이니티 가부시키가이샤 | 저분자 화합물에 의한 내배엽 조직 또는 기관 유래 세포로부터의 줄기/전구 세포의 제작 방법 |
EP4043549A2 (en) * | 2019-08-01 | 2022-08-17 | Industry-Academic Cooperation Foundation, Yonsei University | Medium composition for enhancing wnt protein activity |
CN112553145B (zh) * | 2020-12-25 | 2024-04-02 | 汕头大学医学院 | 一种高效定型内胚层细胞的诱导分化方法 |
AU2022382571A1 (en) * | 2021-11-08 | 2024-05-02 | Vertex Pharmaceuticals Incorporated | Stem cell differentiation and chemical compounds |
Family Cites Families (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5491090A (en) | 1994-02-09 | 1996-02-13 | Westvaco Corporation | Embryogenic coniferous liquid suspension cultures |
AU729377B2 (en) | 1997-10-23 | 2001-02-01 | Asterias Biotherapeutics, Inc. | Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
CA2692325C (en) | 2001-12-07 | 2015-10-20 | Geron Corporation | Islet cells from human embryonic stem cells |
US20060003446A1 (en) * | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
WO2005036839A2 (en) | 2003-10-03 | 2005-04-21 | Avici Systems, Inc. | Rapid alternate paths for network destinations |
WO2005045012A1 (en) * | 2003-11-05 | 2005-05-19 | Regents Of The University Of Minnesota | Endodermal stem cells in liver and methods for isolation thereof |
US7259011B2 (en) | 2004-05-20 | 2007-08-21 | Paul Lucas | Pluripotent adult stem cells |
AU2005272681B2 (en) * | 2004-08-13 | 2009-11-19 | University Of Georgia Research Foundation, Inc. | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
DE102004043256B4 (de) | 2004-09-07 | 2013-09-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Skalierbarer Prozess zur Kultivierung undifferenzierter Stammzellen in Suspension |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
GB0503962D0 (en) | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
WO2007103490A2 (en) | 2006-03-09 | 2007-09-13 | The Scripps Research Institute | System for the expression of orthogonal translation components in eubacterial host cells |
TWI498332B (zh) | 2006-04-26 | 2015-09-01 | Hoffmann La Roche | 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物 |
RU2439074C2 (ru) | 2006-04-26 | 2012-01-10 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К) |
JP5291616B2 (ja) | 2006-04-26 | 2013-09-18 | ジェネンテック, インコーポレイテッド | ホスホイノシチド3−キナーゼ抑制剤化合物およびその使用方法 |
KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Pi3k 억제제로서의 피리미딘 유도체 |
GB0608820D0 (en) | 2006-05-04 | 2006-06-14 | Piramed Ltd | Pharmaceutical compounds |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
CN101541953A (zh) * | 2006-06-02 | 2009-09-23 | 佐治亚大学研究基金会 | 通过从人胚胎干细胞获得的定形内胚层细胞的分化得到胰和肝内胚层细胞及组织 |
CA2654196A1 (en) * | 2006-06-02 | 2007-12-13 | University Of Georgia Research Foundation, Inc. | Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems |
PL2049502T3 (pl) | 2006-07-28 | 2012-06-29 | Novartis Ag | 2,4-Podstawione chinazoliny jako inhibitory kinazy lipidowej |
LT2057156T (lt) | 2006-08-23 | 2017-05-25 | Kudos Pharmaceuticals Limited | 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai |
CA2660758A1 (en) | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
EP2061784A1 (en) | 2006-09-14 | 2009-05-27 | AstraZeneca AB | 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032027A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
US20100022534A1 (en) | 2006-09-14 | 2010-01-28 | Astrazeneca | 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032077A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032041A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
JP2010503650A (ja) | 2006-09-14 | 2010-02-04 | アストラゼネカ アクチボラグ | 増殖性疾患の治療のための、pi3kおよびmtor阻害剤としての2−ベンズイミダゾリル−6−モルホリノ−4−ピペリジン−4−イルピリミジン誘導体 |
CN101595103A (zh) | 2006-09-14 | 2009-12-02 | 阿斯利康(瑞典)有限公司 | 嘧啶衍生物 |
WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
US20090318410A1 (en) | 2006-10-30 | 2009-12-24 | Novartis Ag | Imidazopyridazines as lipid kinase inhibitors |
MY180595A (en) | 2006-12-07 | 2020-12-03 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
TW200829594A (en) | 2006-12-07 | 2008-07-16 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
AU2008237715A1 (en) | 2007-04-12 | 2008-10-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
GB0707087D0 (en) | 2007-04-12 | 2007-05-23 | Piramed Ltd | Pharmaceutical compounds |
CN101765597A (zh) | 2007-04-12 | 2010-06-30 | 霍夫曼-拉罗奇有限公司 | 作为磷脂酰肌醇-3-激酶抑制剂的嘧啶衍生物 |
AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
ATE510841T1 (de) | 2007-06-12 | 2011-06-15 | Hoffmann La Roche | Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase |
WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
WO2008152394A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
BRPI0814818A2 (pt) | 2007-07-09 | 2019-09-10 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo e um efeito inibitório de mtor quinase em uma animal de sangue quente, método para tratar doenças, e, composição farmacêutica |
EP2207781B1 (en) | 2007-09-24 | 2012-11-28 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
US8129371B2 (en) | 2007-10-16 | 2012-03-06 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors |
GB0721095D0 (en) | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
US20110230464A1 (en) | 2007-10-26 | 2011-09-22 | Paul Goldsmith | Purine derivatives useful as p13 kinase inhibitors |
WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
WO2009070524A1 (en) | 2007-11-27 | 2009-06-04 | Wyeth | Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors |
AR069798A1 (es) | 2007-12-20 | 2010-02-17 | Novartis Ag | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. |
CN101939319A (zh) | 2007-12-20 | 2011-01-05 | 诺瓦提斯公司 | 联噻唑衍生物、它们的制备方法以及它们作为药物的用途 |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
MY191407A (en) | 2008-01-04 | 2022-06-27 | Intellikine Llc | Certain chemical entities, compositions and methods |
CA2712267A1 (en) | 2008-01-15 | 2009-07-23 | Wyeth Llc | 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
CA2711759A1 (en) | 2008-01-30 | 2009-08-06 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
US20090192176A1 (en) | 2008-01-30 | 2009-07-30 | Wyeth | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
WO2009097515A2 (en) | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US20090227575A1 (en) | 2008-03-04 | 2009-09-10 | Wyeth | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
MX2010010659A (es) | 2008-03-31 | 2010-10-26 | Genentech Inc | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. |
DK2271634T3 (da) | 2008-04-29 | 2014-05-05 | Integrative Res Lab Sweden Ab | Modulatorer af dopamin-neurotransmission |
PT3216793T (pt) | 2008-05-23 | 2019-05-30 | Wyeth Llc | Compostos de triazina como inibidores de pi3 quinase e mtor |
US20090298820A1 (en) | 2008-05-28 | 2009-12-03 | Wyeth | 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
EP2300460A1 (en) | 2008-05-28 | 2011-03-30 | Wyeth LLC | 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US8158624B2 (en) | 2008-05-30 | 2012-04-17 | Genetech, Inc. | Purine PI3K inhibitor compounds and methods of use |
WO2010002954A1 (en) | 2008-07-02 | 2010-01-07 | Wyeth | (2-aryl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US8358269B2 (en) | 2008-07-18 | 2013-01-22 | Intel Corporation | Human interface device (HID) |
WO2010011620A1 (en) | 2008-07-21 | 2010-01-28 | Wyeth | 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
WO2010014939A1 (en) | 2008-07-31 | 2010-02-04 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
US20100028307A1 (en) | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
ES2502917T3 (es) | 2008-08-12 | 2014-10-06 | Wyeth Llc | Compuestos de pirrol[4,3,2-de]quinolin-8-amina y procedimientos de preparación y uso de los mismos |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2010030727A1 (en) | 2008-09-10 | 2010-03-18 | Wyeth Llc | 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US20100068204A1 (en) | 2008-09-12 | 2010-03-18 | Wyeth | 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents |
JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン, エルエルシー | 複素環キナーゼ阻害剤 |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8008075B2 (en) | 2008-11-04 | 2011-08-30 | Viacyte, Inc. | Stem cell aggregate suspension compositions and methods of differentiation thereof |
US20110269779A1 (en) | 2008-11-18 | 2011-11-03 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
WO2010059788A1 (en) | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
JP5709766B2 (ja) | 2009-03-12 | 2015-04-30 | ジェネンテック, インコーポレイテッド | 造血器腫瘍の治療のためのホスホイノシチド3キナーゼ阻害剤化合物と化学療法剤の併用 |
EP2233566A1 (en) * | 2009-03-17 | 2010-09-29 | Vrije Universiteit Brussel | Generation of pancreatic progenitor cells |
WO2010129816A2 (en) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
AU2010254161A1 (en) | 2009-05-27 | 2011-11-10 | F. Hoffmann-La Roche Ag | Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use |
WO2010136583A2 (en) * | 2009-05-29 | 2010-12-02 | Novo Nordisk A/S | INDUCED DERIVATION OF SPECIFIC ENDODERM FROM hPS CELL-DERIVED DEFINITIVE ENDODERM |
EP2445346A4 (en) | 2009-06-24 | 2012-12-05 | Genentech Inc | OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
CN102471351A (zh) | 2009-07-02 | 2012-05-23 | 诺瓦提斯公司 | 用作pi3k抑制剂的2-羧酰胺环氨基脲 |
EP2457998A4 (en) * | 2009-07-23 | 2013-08-21 | Beijing Huayuanbochuang Technology Co Ltd | METHODS FOR OBTAINING HEPATIC CELLS, HEPATIC ENDODERM CELLS, AND HEPATIC PRECURSOR CELLS BY INDUCING THE DIFFERENTIATION |
JPWO2011016485A1 (ja) * | 2009-08-04 | 2013-01-10 | 国立大学法人 岡山大学 | iPS細胞から肝実質細胞への分化誘導方法 |
BR112012003709B1 (pt) | 2009-08-17 | 2021-05-18 | Intellikine Llc | compostos heterocíclicos e usos dos mesmos |
PE20121559A1 (es) | 2009-09-28 | 2012-12-05 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la p13k |
EP2498780B1 (en) | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
RU2515541C2 (ru) | 2009-11-12 | 2014-05-10 | Ф.Хоффманн-Ля Рош Аг | N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения |
US20130031645A1 (en) * | 2009-11-25 | 2013-01-31 | Thomas Touboul | Method for hepatic differentiation of definitive endoderm cells |
CA2786294A1 (en) | 2010-02-22 | 2011-08-25 | F. Hoffmann-La Roche Ag | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
JP6159529B2 (ja) * | 2010-03-23 | 2017-07-05 | 株式会社クラレ | 多能性哺乳細胞を分化させる培養方法 |
US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
JP5894980B2 (ja) | 2010-05-24 | 2016-03-30 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
WO2012056997A1 (ja) * | 2010-10-28 | 2012-05-03 | 国立大学法人熊本大学 | 多能性幹細胞の分化誘導効率を改善するための方法及び培地 |
-
2013
- 2013-05-21 KR KR1020167004226A patent/KR20160027218A/ko active Search and Examination
- 2013-05-21 KR KR1020167004225A patent/KR20160027217A/ko not_active Application Discontinuation
- 2013-05-21 US US14/436,743 patent/US20170002313A1/en not_active Abandoned
- 2013-05-21 RU RU2014149145A patent/RU2014149145A/ru not_active Application Discontinuation
- 2013-05-21 CN CN201380026250.6A patent/CN104350144B/zh not_active Expired - Fee Related
- 2013-05-21 JP JP2015513134A patent/JP6301316B2/ja not_active Expired - Fee Related
- 2013-05-21 KR KR1020147032535A patent/KR101761464B1/ko active IP Right Grant
- 2013-05-21 CN CN201510561606.7A patent/CN105062961A/zh active Pending
- 2013-05-21 EP EP13724574.2A patent/EP2852661A1/en not_active Withdrawn
- 2013-05-21 WO PCT/EP2013/060372 patent/WO2013174794A1/en active Application Filing
- 2013-05-21 MX MX2014013725A patent/MX2014013725A/es unknown
- 2013-05-21 KR KR1020167004227A patent/KR20160027219A/ko active IP Right Grant
- 2013-05-21 BR BR112014028881A patent/BR112014028881A2/pt not_active IP Right Cessation
- 2013-05-21 CA CA2868392A patent/CA2868392A1/en not_active Abandoned
-
2015
- 2015-08-10 HK HK15107688.5A patent/HK1207114A1/xx not_active IP Right Cessation
-
2016
- 2016-03-14 HK HK16102908.9A patent/HK1215043A1/zh unknown
-
2017
- 2017-01-24 JP JP2017009924A patent/JP2017113005A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013174794A1 (en) | 2013-11-28 |
KR20160027219A (ko) | 2016-03-09 |
KR20160027218A (ko) | 2016-03-09 |
RU2014149145A (ru) | 2016-07-20 |
JP2017113005A (ja) | 2017-06-29 |
CN104350144A (zh) | 2015-02-11 |
HK1215043A1 (zh) | 2016-08-12 |
EP2852661A1 (en) | 2015-04-01 |
KR20160027217A (ko) | 2016-03-09 |
JP6301316B2 (ja) | 2018-03-28 |
BR112014028881A2 (pt) | 2017-06-27 |
US20170002313A1 (en) | 2017-01-05 |
KR101761464B1 (ko) | 2017-07-25 |
MX2014013725A (es) | 2015-02-10 |
CN105062961A (zh) | 2015-11-18 |
KR20150008418A (ko) | 2015-01-22 |
CN104350144B (zh) | 2017-08-04 |
JP2015523063A (ja) | 2015-08-13 |
CA2868392A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215043A1 (zh) | 獲得和使用內胚層和肝細胞的組合物和方法 | |
HK1216851A1 (zh) | 用於提高細胞存活力的組合物和使用該組合物的方法 | |
HK1215785A1 (zh) | 控制釋放組合物及使用方法 | |
IL237479B (en) | Methods and compositions relating to eukaryotic cell modulators | |
HK1210494A1 (zh) | 用於細胞培養的裝置和方法 | |
EP2836224A4 (en) | COMPOSITIONS OF BIOZOOSE AND RELATED METHODS | |
EP2861612A4 (en) | METHODS FOR PREPARING PLURIPOTENT STEM CELLS | |
GB201200458D0 (en) | Methods of preparing cells and compositions | |
EP2667889A4 (en) | WNT COMPOSITIONS AND METHODS OF USE THEREOF | |
HK1205185A1 (en) | Methods and composition related to brown adipose-like cells | |
HK1215719A1 (zh) | 免疫抑制細胞及其製造和使用方法 | |
IL266965B (en) | Preparations containing pancreatic progenitor cells that are not multipurpose, and methods for their preparation | |
ZA201406267B (en) | Controlled release compositions and their methods of use | |
HK1210436A1 (en) | Novel cell compositions and methods | |
EP2859071A4 (en) | CHEMICAL COMPOSITIONS AND METHODS OF USE | |
HK1219292A1 (zh) | +細胞組合物及其使用方法 | |
EP2841164A4 (en) | COMPOSITIONS AND USE PROCEDURES FOR THE SKIN |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220524 |